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Background
Adoptive cell transfer of Treg cells is a promising
approach to restore tolerance in autoimmune disease.
However the various type of Tregs, their doses of
injection and their in vivo-suppressive mechanism need
to be precisely define to clearly establish which Tregs
will be able to dampen efficiently the immune response
in the various settings.
In our study, we compared the therapeutic potential of
induced CD25+FoxP3+ and two IL10-secreting Tregs:
Tr1 and CD49b-induced Tregs.
Materials and methods
CD49b Treg cells were generated in naive mice following
repetitive injections of iDC. The purification was based on
the negative selection of CD4 T cells isolated from the
spleen and liver of the iDC-vaccinated mice.
Cell sorting experiments were realized to obtain 98%
pure CD49b+ T or CD25+ cells. Collagen type II (bCII)
specific Tr1 clones were obtained from TCR transgenic
mice and expanded in vitro. Selected clones showed in
vitro antigen specificity, Tr1 cytokine profile and IL10-
and TGFb-dependent suppressive activity.
Results
Several doses of CD49b or Tr1 cells were injected i.v. at
day 28 in established collagen-induced arthritis. Clinical
signs of arthritis were scored, as well as biological para-
meters such as the level of anti-bCII antibodies in sera and
the cytokine profile of bCII specific T cells.
We defined for both Treg cell populations the dose
effect in curative settings experiments. One single dose of
3x106 or 1x106 of Tr1 cell administration could reduce
the incidence and severity of CIA. Interestingly, higher
dose of 10M of Tr1 cells did not improve the disease. In
the same manner, the dose of 105 CD4CD49b+ or CD25+
cells reverse clinical symptom with a lack of efficacy of
higher doses. The cytokinic profile of the Tr1 cells was
also investigated in inflammatory settings as well as the
impact of the various Treg cells on the proliferation of
effector cells in vivo.
Conclusions
Our results suggest that even if the Treg cells present
some similarities, we need to precisely define the dose
and type of Treg that will be efficient in each experi-
mental setting.
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